We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pushes Risk-Based Patient Selection for Microbial Vector Therapies
FDA Pushes Risk-Based Patient Selection for Microbial Vector Therapies
November 5, 2015
The FDA is calling for risk management plans for clinical development of microbial vectors for gene therapy, focusing on the potential for vectors to germinate, regerminate or reseed.